Table 4 The predictive efficiency of the risk stratification system for cervical metastatic lymph node in PTC patients
Suspicious US features | No. of Cases | No. of Malignancy LNs | Actual Malignancy rate (%) | Predicted Malignancy risk (%) |
|---|---|---|---|---|
None of suspicious US features | 93 | 2 | 2.2% | 0-10.7% |
Any one of the following suspicious US features | 278 | 149 | 53.6% | 23.4 – 75.1% |
Absence of fatty hilum | 232 | 132 | 56.9% | 53.7% |
Cystic components | 1 | 1 | 100.0% | 36.6% |
Round shape (SD/LD ≥ 0.5) | 34 | 9 | 26.5% | 16.5% |
Hyperechogenicity | ||||
Hyper and hypo-echogenicity (non-uniformity) | 1 | 1 | 100.0% | 33.6% |
Hyper-echogenicity (uniformity) | 2 | 2 | 100.0% | 69.8% |
Calcifications | ||||
Microcalcification | 2 | 1 | 50.0% | 48.5% |
Macrocalcifications | – | – | – | 23.6% |
Abundant vascularity | 6 | 4 | 66.7% | 45.6% |
Any two suspicious US features | 569 | 433 | 76.1% | 33.8 – 95.7% |
Any three suspicious US features | 487 | 452 | 92.8% | 68.3 – 99.4% |
Any four suspicious US features | 267 | 264 | 98.9% | 91.2 – 99.9% |
Any five suspicious US features | 96 | 96 | 100.0% | 98.6 – 100.0% |
All of six suspicious US features | 15 | 15 | 100.0% | 99.9 – 100.0% |